Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.
J Neuroimmunol. 2013 Mar 18. pii: S0165-5728(13)00051-9. doi: 10.1016/j.jneuroim.2013.02.013. [Epub ahead of print]
Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.
Source
Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Abstract
We investigated the efficiency of nasal drug administration as a new non-invasive treatment strategy for MS. Glatiramer Acetate (GA) and GA-Cannabidiol (CBD) combination administered in nasal delivery system (NDS) resulted in a statistically significant decrease of clinical scores and inflammatory cytokine expression in experimental autoimmune encephalomyelitis (EAE) mice. Even a suboptimal dose of Prednisolone in NDS was effective in preventing the clinical signs of the disease. Neuron regeneration was observed in the hippocampus of EAE mice treated with GA-CBD in NDS. This work shows that nasal administration improved drug efficiency and stimulates further research for a non-invasive strategy for MS.
Copyright © 2013 Elsevier B.V. All rights reserved.
- PMID:
23517929
[PubMed – as supplied by publisher]
MeSH Terms, Substances
MeSH Terms
- Administration, Intranasal
- Animals
- Cannabidiol/administration & dosage*
- Encephalomyelitis, Autoimmune, Experimental/drug therapy*
- Encephalomyelitis, Autoimmune, Experimental/pathology
- Female
- Immunosuppressive Agents/administration & dosage*
- Mice
- Mice, Inbred C57BL
- Multiple Sclerosis/drug therapy
- Nerve Regeneration/drug effects
- Peptides/administration & dosage*
